Global state: non‐responders to the first injection · psychosis‐induced aggression or agitation (rapid tranquillisation)
ARIPIPRAZOLE (IM) showed no clear difference in global state: non‐responders to the first injection compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (low certainty).
1 finding from 1 review
Adverse effects: one or more adverse events during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: one or more adverse events during 24 hours (only… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Adverse effects: movement disorders ‐ EPS during 24 hours (only reported if occurred in ≥ 5% of people) · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes adverse effects: movement disorders ‐ EPS during 24 hours (only… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Economic outcomes · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Tranquillisation or asleep · psychosis‐induced aggression or agitation (rapid tranquillisation)
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Repeated need for tranquillisation ‐ needing additional injections during 24 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes repeated need for tranquillisation ‐ needing additional injections… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Specific behaviour: Agitation ‐ clinically important change (PANSS ‐EC reduction ≥ 40% from baseline) ‐ up to 2 hours · psychosis‐induced aggression or agitation (rapid tranquillisation)
It is very uncertain whether ARIPIPRAZOLE (IM) changes specific behaviour: Agitation ‐ clinically important change (PANSS… compared with OTHER ANTIPSYCHOTIC: a. HALOPERIDOL (very low certainty).
1 finding from 1 review
Clinical response: no clinically significant response in mental state · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Weight gain · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Clinical response: mean score/change in global state · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Mental state · people with treatment‐resistant schizophrenia
1 finding from 1 review
Acceptability of treatment ‐ leaving the study early · people with treatment‐resistant schizophrenia
It is very uncertain whether CLOZAPINE + ARIPIPRAZOLE changes leaving the study early: acceptability of treatment ‐ as measured by… compared with CLOZAPINE + HALOPERIDOL (Cipriani 2013) (very low certainty).
1 finding from 1 review
Service utilisation outcomes: hospital admission or days in hospital · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Quality of life/satisfaction with care for either recipients of care or carers: significant change in quality of life/satisfaction · people with treatment‐resistant schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found